Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Adjunctive Devices for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Slide: 33 of 39

Adjunctive Distal Balloon Embolic Protection Devices Versus PCI Alone in Patients With STEMI: Final and Intermediate Health Outcomes

In RCTs, the use of distal balloon embolic protection devices did not significantly impact mortality, MI, stroke, or MACE versus a control when using the longest duration of followup.

In RCTs, the use of distal balloon embolic protection devices significantly increased the occurrence of MBG-3 and TIMI-3 blood flow but did not significantly impact ST-segment resolution, ejection fraction, distal embolization, or no reflow versus a control. For TIMI-3 blood flow [RD 0.08 (0.02, 0.14, (CER 0.69 to 1.00)], for every 13 patients who undergo surgery with a distal balloon embolic protection device 1 will achieve TIMI-3 blood flow. For MBG-3 [RD 0.15 (0.10, 0.24), (CER 0.20 to 0.53)], seven people would need to be treated with a distal balloon embolic protection device to cause one person to experience a MBG-3.